SPRO
Spero Therapeutics, Inc.Company Information
- Company Name
- Spero Therapeutics, Inc.
- CIK
- CIK0001701108
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- SPRO: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- SPRO
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-05-04
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 202,259
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 21,177,166
- Shares outstanding
- 57,968,608
- Ownership
- 36.53%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- 1.68%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 51 | 56 | 40 | 49 | 31 | 49 | 53 | 76 | 64 | 82 | 76 | 94 | ||||||
| Other Assets Current | 0 | 0 | 0 | 2 | 2 | 1 | 3 | 3 | 5 | 5 | 2 | 3 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 2 | 1 | 1 | 2 | 2 | 2 | 3 | 4 | 4 | 5 | ||||||
| Assets Current | 52 | 58 | 67 | 52 | 59 | 75 | 107 | 132 | 122 | 140 | 131 | 102 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | ||||||
| Property Plant And Equipment Net | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 53 | 59 | 69 | 54 | 62 | 78 | 111 | 135 | 150 | 168 | 182 | 107 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 0 | 0 | 1 | 1 | 1 | 2 | 7 | 6 | 3 | 3 | 1 | 1 | ||||||
| Operating Lease Liability Current | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Taxes Payable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | ||||||
| Deferred Revenue Current | - | - | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 3 | 2 | 14 | ||||||
| Liabilities Current | 8 | 5 | 9 | 14 | 15 | 29 | 49 | 49 | 46 | 42 | 37 | 25 | ||||||
| Operating Lease Liability Noncurrent | 0 | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 3 | 4 | 4 | 4 | ||||||
| Deferred Revenue Noncurrent | - | - | 0 | 13 | 13 | 13 | 12 | 12 | 9 | 10 | 11 | 24 | ||||||
| Other Long Term Debt Noncurrent | 0 | 0 | 0 | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 9 | 6 | 10 | 28 | 29 | 44 | 64 | 70 | 69 | 71 | 75 | 53 | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 512 | 511 | 510 | 509 | 508 | 507 | 506 | 504 | 502 | 500 | 498 | 496 | ||||||
| Retained Earnings Accumulated Deficit | -468 | -458 | -451 | -483 | -475 | -474 | -460 | -439 | -422 | -404 | -391 | -442 | ||||||
| Stockholders Equity | 44 | 53 | 59 | 26 | 33 | 34 | 46 | 66 | 81 | 96 | 107 | 54 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Liabilities And Stockholders Equity | 53 | 59 | 69 | 54 | 62 | 78 | 111 | 135 | 150 | 168 | 182 | 107 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 240 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | ||||||
| Common Stock Shares Issued | 58 | 58 | 56 | 56 | 56 | 56 | 55 | 54 | 54 | 54 | 53 | 53 | ||||||
| Shares Outstanding | 58 | 58 | 56 | 56 | 56 | 56 | 55 | 54 | 54 | 54 | 53 | 53 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialSpero Therapeutics, Inc. (SPRO) — SEC Financial Statements & Analysis
Spero Therapeutics, Inc. (SPRO) is a pharmaceutical preparations company, incorporated in DE. Spero Therapeutics, Inc. trades on Nasdaq as: SPRO. Spero Therapeutics, Inc. (SPRO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, Spero Therapeutics, Inc. carries a market cap of $128.11M, a P/E ratio of 17.35x, a P/B ratio of 2.90x, a P/S ratio of 9.98x, an enterprise value of $77.34M, and an EV/EBITDA multiple of 12.84x. On profitability, it posts an operating margin of 46.95%, a net margin of 57.54%, a Return on Equity (ROE) of 19.17%, a Return on Assets (ROA) of 12.85%, and a Return on Invested Capital (ROIC) of 103.09%. Per share, it reports EPS of $0.13, diluted EPS of $0.13, free cash flow per share of $0.34, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 9847.29% year-over-year, net income growth of -113.77% year-over-year, and EPS growth of -113.31% year-over-year. On the balance sheet, it maintains a current ratio of 6.12x, a quick ratio of 6.03x, working capital of $43.16M, a debt-to-equity ratio of 0.19x, a debt ratio of 0.16, free cash flow of $19.58M (TTM), and net debt of $-50.77M. Figures sourced from SEC EDGAR.
- Market Cap
- $128.11M
- P/E TTM
- 17.35x
- EPS TTM
- $0.13
- P/B TTM
- 2.90x
- ROE TTM
- 19.17%
- ROA TTM
- 12.85%
- Debt To Equity
- 0.19x
- Free Cash Flow TTM
- $19.58M
- Net Revenue TTM Growth 1Y
- 9847.29%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Spero Therapeutics, Inc. in?
Spero Therapeutics, Inc. (SPRO) operates in the Pharmaceutical Preparations industry.
What exchange does SPRO trade on?
Spero Therapeutics, Inc. (SPRO) trades on the Nasdaq.
Where is Spero Therapeutics, Inc. incorporated?
Spero Therapeutics, Inc. is incorporated in DE.
When was Spero Therapeutics, Inc. (SPRO)'s most recent SEC filing?
Spero Therapeutics, Inc. (SPRO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is SPRO's market cap?
Spero Therapeutics, Inc. (SPRO) has a market capitalization of $128.11M as of 2026-06-30.
What is SPRO's P/E ratio?
Spero Therapeutics, Inc. (SPRO)'s trailing twelve month P/E ratio is 17.35x as of 2026-06-30.
What is SPRO's EPS (earnings per share)?
Spero Therapeutics, Inc. (SPRO)'s trailing twelve month EPS is $0.13 as of 2026-06-30.
What is SPRO's ROE (return on equity)?
Spero Therapeutics, Inc. (SPRO)'s trailing twelve month Return on Equity (ROE) is 19.17% as of 2026-06-30.
What is SPRO's ROA (return on assets)?
Spero Therapeutics, Inc. (SPRO)'s trailing twelve month Return on Assets (ROA) is 12.85% as of 2026-06-30.
What is SPRO's ROIC (return on invested capital)?
Spero Therapeutics, Inc. (SPRO)'s trailing twelve month Return on Invested Capital (ROIC) is 103.09% as of 2025-12-31.
What is SPRO's EV/EBITDA?
Spero Therapeutics, Inc. (SPRO)'s trailing twelve month EV/EBITDA is 12.84x as of 2026-06-30.